REGENXBIO
-$0.28 (-0.63%) As of 5:39 PM UTC today
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell REGENXBIO and other ETFs, options, and stocks.
About RGNX
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors; and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381.
CEO
Kenneth T. Mills
Employees
306
Headquarters
Rockville, Maryland
Founded
2008
RGNX Key Statistics
Market Cap
1.91B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
716.78K
High Today
$45.00
Low Today
$42.93
Open Price
$44.98
Volume
313.65K
52 Week High
$50.26
52 Week Low
$25.93
RGNX News
BenzingaSep 15
Looking Into Regenxbio's Return On Capital Employed
Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.04 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 18.58%, resul
Analyst Ratings
75%
of 8 ratings
Buy
75%
Hold
25%
Sell
0%
RGNX Earnings
-$1.36
-$0.83
-$0.30
$0.23
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
Expected Nov 3, After Hours
